Linjing Mu

Last Name

Mu

First Name

Linjing

ORCID

0000-0001-5354-1546

Organisational unit

03688 - Schibli, Roger / Schibli, Roger

Show all metadata

Search Results

Publications 1 - 10 of 114

In vivo Imaging of Cannabinoid Type 2 Receptors: Functional and Structural Alterations in Mouse Model of Cerebral Ischemia by PET and MRI
Ni, Ruiqing; Müller Herde, Adrienne; Haider, Ahmed; et al. (2022)
Molecular Imaging and Biology
Purpose Stroke is one of the most prevalent vascular diseases. Non-invasive molecular imaging methods have the potential to provide critical insights into the temporal dynamics and follow alterations of receptor expression and metabolism in ischemic stroke. The aim of this study was to assess the cannabinoid type 2 receptor (CB2R) levels in transient middle cerebral artery occlusion (tMCAO) mouse models at subacute stage using positron emission tomography (PET) with our novel tracer [18F]RoSMA-18-d6 and structural imaging by magnetic resonance imaging (MRI). Procedures Our recently developed CB2R PET tracer [18F]RoSMA-18-d6 was used for imaging neuroinflammation at 24 h after reperfusion in tMCAO mice. The RNA expression levels of CB2R and other inflammatory markers were analyzed by quantitative real-time polymerase chain reaction using brain tissues from tMCAO (1 h occlusion) and sham-operated mice. [18F]fluorodeoxyglucose (FDG) was included for evaluation of the cerebral metabolic rate of glucose (CMRglc). In addition, diffusion-weighted imaging and T2-weighted imaging were performed for anatomical reference and delineating the lesion in tMCAO mice. Results mRNA expressions of inflammatory markers TNF-α, Iba1, MMP9 and GFAP, CNR2 were increased to 1.3–2.5 fold at 24 h after reperfusion in the ipsilateral compared to contralateral hemisphere of tMCAO mice, while mRNA expression of the neuronal marker MAP-2 was markedly reduced to ca. 50 %. Reduced [18F]FDG uptake was observed in the ischemic striatum of tMCAO mouse brain at 24 h after reperfusion. Although higher activity of [18F]RoSMA-18-d6 in ex vivo biodistribution studies and higher standard uptake value ratio (SUVR) were detected in the ischemic ipsilateral compared to contralateral striatum in tMCAO mice, the in vivo specificity of [18F]RoSMA-18-d6 was confirmed only in the CB2R-rich spleen. Conclusions This study revealed an increased [18F]RoSMA-18-d6 measure of CB2R and a reduced [18F]FDG measure of CMRglc in the ischemic striatum of tMCAO mice at subacute stage. [18F]RoSMA-18-d6 might be a promising PET tracer for detecting CB2R alterations in animal models of neuroinflammation without neuronal loss.
Radiation dosimetry of [18F]-PSS232—a PET radioligand for imaging mGlu5 receptors in humans
Sah, Bert-Ram; Sommerauer, Michael; Mu, Linjing; et al. (2019)
EJNMMI Research
Purpose (E)-3-(pyridin-2-ylethynyl)cyclohex-2-enone O-(3-(2-[18F]-fluoroethoxy)propyl) oxime ([18F]-PSS232) is a new PET tracer for imaging of metabotropic glutamate receptor subtype 5 (mGlu5), and has shown promising results in rodents and humans. The aim of this study was to estimate the radiation dosimetry and biodistribution in humans, to assess dose-limiting organs, and to demonstrate safety and tolerability of [18F]-PSS232 in healthy volunteers. Methods PET/CT scans of six healthy male volunteers (mean age 23.5 ± 1.7; 21–26 years) were obtained after intravenous administration of 243 ± 3 MBq of [18F]-PSS232. Serial whole-body (vertex to mid-thigh) PET scans were assessed at ten time points, up to 90 min after tracer injection. Calculation of tracer kinetics and cumulated organ activities were performed using PMOD 3.7 software. Dosimetry estimates were calculated using the OLINDA/EXM software. Results Injection of [18F]-PSS232 was safe and well tolerated. Organs with highest absorbed doses were the gallbladder wall (0.2295 mGy/MBq), liver (0.0547 mGy/MBq), and the small intestine (0.0643 mGy/MBq). Mean effective dose was 3.72 ± 0.12 mSv/volunteer (range 3.61–3.96 mSv; 0.0153 mSv/MBq). Conclusion [18F]-PSS232, a novel [18F]-labeled mGlu5 tracer, showed favorable dosimetry values. Additionally, the tracer was safe and well tolerated.
Structure-Affinity Relationships of 2,3,4,5-Tetrahydro-1 H-3-benzazepine and 6,7,8,9-Tetrahydro-5 H-benzo[7]annulen-7-amine Analogues and the Discovery of a Radiofluorinated 2,3,4,5-Tetrahydro-1 H-3-benzazepine Congener for Imaging GluN2B Subunit-Containing N-Methyl-d-aspartate Receptors
Ahmed, Hazem; Haider, Ahmed; Varisco, Jasmine; et al. (2019)
Journal of Medicinal Chemistry
In Vitro and in Vivo Characterization of Novel 18F-Labeled Bombesin Analogues for Targeting GRPR-Positive Tumors
Mu, Linjing; Honer, Michael; Becaud, Jessica; et al. (2010)
Bioconjugate Chemistry
Syntheses and pharmacological characterization of novel thiazole derivatives as potential mGluR5 PET ligands
Baumann, Cindy A.; Mu, Linjing; Wertli, Nicole; et al. (2010)
Bioorganic & Medicinal Chemistry
Positron emission tomography of type 2 cannabinoid receptors for detecting inflammation in the central nervous system
Ni, Ruiqing; Mu, Linjing; Ametamey, Simon M. (2019)
Acta Pharmacologica Sinica
Cannabinoid receptor CB₂ (CB₂R) is upregulated on activated microglia and astrocytes in the brain under inflammatory conditions and plays important roles in many neurological diseases, such as Alzheimer’s disease, amyotrophic lateral sclerosis, and ischemic stroke. The advent of positron emission tomography (PET) using CB₂R radiotracers has enabled the visualization of CB₂R distribution in vivo in animal models of central nervous system inflammation, however translation to humans has been less successful. Several novel CB₂R radiotracers have been developed and evaluated to quantify microglial activation. In this review, we summarize the recent preclinical and clinical imaging results of CB₂R PET tracers and discuss the prospects of CB₂R imaging using PET.
Discovery of a Fluorinated 4-Oxo-Quinoline Derivative as a Potential PET Radiotracer for Targeting CB2 Receptor
Mu, Linjing; Slavik, R.; Muller, A.H.; et al. (2015)
European Journal of Nuclear Medicine and Molecular Imaging
Radioligand development for imaging cannabinoid receptor subtype 2 with PET
Mu, Linjing; Slavik, R.; Muller, A.; et al. (2014)
European Journal of Nuclear Medicine and Molecular Imaging
Synthesis and In Vitro Evaluation of E- and Z-Geometrical Isomers of PSS232 as Potential Metabotropic Glutamate Receptors Subtype 5 (mGlu(5)) Binders
Milicevic Sephton, Selena; Mu, Linjing; Dragic, Martina; et al. (2013)
Synthesis
4-[F-18]Fluoroglutamic Acid (BAY 85-8050), a New Amino Acid Radiotracer for PET Imaging of Tumors Synthesis and in Vitro Characterization
Krasikova, Raisa N.; Kuznetsova, Olga F.; Fedorova, Olga S.; et al. (2011)
Journal of Medicinal Chemistry

Publications 1 - 10 of 114

Linjing Mu

Last Name

First Name

ORCID

Organisational unit

Filters

Search Results